for coverage from TIME, Health, Fortune and more
Go »
Pfizer In Merger Talks With Allergan PLC
Pfizer headquarters in New York City. Spencer Platt Getty Images

Pfizer Defeats Appeals Over Zoloft Birth Defects

Jun 02, 2017

Pfizer (pfe) on Friday defeated an effort to revive more than 300 lawsuits alleging that its antidepressant Zoloft causes cardiac birth defects in children when taken by women during early pregnancy.

A panel of the 3rd U.S. Circuit Court of Appeals in Philadelphia upheld the April 2016 dismissal of the cases by a lower court judge, who said the plaintiffs had not shown a plausible scientific link between Zoloft and the birth defects.

The panel said the judge properly excluded testimony from Nicholas Jewell, a professor at the University of California at Berkeley who the plaintiffs wanted to call as an expert witness to establish the link, because it was not sufficiently reliable.

"Courts are supposed to ensure that the testimony given to the jury is reliable and will be more informative than confusing," Circuit Judge Jane Roth wrote for the three-judge panel. "Dr. Jewell's application of his purported methods does not satisfy this standard."

Lawyers for the plaintiffs did not immediately respond to requests for comment. Pfizer had no immediate comment.

Zoloft is part of a popular group of antidepressants known as selective serotonin reuptake inhibitors, or SSRIs.

The plaintiffs accused Pfizer of downplaying Zoloft's risks to boost sales.

All products and services featured are based solely on editorial selection. FORTUNE may receive compensation for some links to products and services on this website.

Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc. Dow Jones Terms & Conditions: S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions